Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 17, 2014
A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancerJoyce Chai, A Forbes Howie, David A Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysisSorrel E Wolowacz, David A Cameron, Helen C Tate, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerRichard A Anderson, Mikkel Rosendahl, Thomas W Kelsey, et al.
Bulletin of Mathematical Biology|October 3, 2007
Optimal reproduction strategies in two species of mound-building termitesDavid A Cameron, David J Ivers, Theodore A Evans, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 31, 2015
Reelin Prevents Apical Neurite Retraction during Terminal Translocation and Dendrite InitiationRyan S O'Dell, David A Cameron, Warren R Zipfel, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2008
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patientsChristoph C Zielinski, Ahmad Awada, David A Cameron, et al.
Molecular Endocrinology (Baltimore, Md.)|August 2, 2007
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistanceCatherine Naughton, Kenneth MacLeod, Barbara Kuske, et al.
Molecular Vision|August 4, 2010
Retinal ectopias and mechanically weakened basement membrane in a mouse model of muscle-eye-brain (MEB) disease congenital muscular dystrophyHuaiyu Hu, Joseph Candiello, Peng Zhang, et al.
Pharmacoeconomics|April 21, 2011
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrencePeter S Hall, Claire Hulme, Christopher McCabe, et al.
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|July 17, 2014
A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancerJoyce Chai, A Forbes Howie, David A Cameron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2008
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysisSorrel E Wolowacz, David A Cameron, Helen C Tate, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2013
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerRichard A Anderson, Mikkel Rosendahl, Thomas W Kelsey, et al.
Bulletin of Mathematical Biology|October 3, 2007
Optimal reproduction strategies in two species of mound-building termitesDavid A Cameron, David J Ivers, Theodore A Evans, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 31, 2015
Reelin Prevents Apical Neurite Retraction during Terminal Translocation and Dendrite InitiationRyan S O'Dell, David A Cameron, Warren R Zipfel, et al.
Molecular Cancer Therapeutics|January 24, 2007
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingPeter Mullen, David A Cameron, Max Hasmann, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2008
The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patientsChristoph C Zielinski, Ahmad Awada, David A Cameron, et al.
Molecular Endocrinology (Baltimore, Md.)|August 2, 2007
Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistanceCatherine Naughton, Kenneth MacLeod, Barbara Kuske, et al.
Molecular Vision|August 4, 2010
Retinal ectopias and mechanically weakened basement membrane in a mouse model of muscle-eye-brain (MEB) disease congenital muscular dystrophyHuaiyu Hu, Joseph Candiello, Peng Zhang, et al.
Pharmacoeconomics|April 21, 2011
Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrencePeter S Hall, Claire Hulme, Christopher McCabe, et al.
Pageof 14